Bradu, Dan published the artcileBiosimilar branded iodinated contrast agents related to the largest number of reports to the WHO-Pharmacovigilance System over the first 40 years of the programme, Recommanded Product: Diatrizoic Acid, the main research area is biosimilar iodinated contrast agent.
Anal. of the side-events, and suspicious or confirmed adverse drug reactions (SADRs), accounting for a total of 67,232 reports, based on the model and on a Matlab program (as described in the fourth contribution of our current series) showed broadly inhomogeneous profiles of all of the 10 products categorized as “”biosimilar”” that have been the object of the largest number of reports in the first 40 years of the WHO Pharmacovigilance Program. The anal. highlighted striking differences both when they were subdivided into system-organ class disorders (SOCDs) or studied together, and when they were analyzed in terms of five pairs of biosimilars and their resp., agreed, generic reference products. These conclusions add to the data, already reported by the authors, of the preclin. experiments and the pre-marketing conventional standardized clin. trials regulations.
Pharmacologyonline published new progress about Biosimilars. 117-96-4 belongs to class isoquinoline, name is Diatrizoic Acid, and the molecular formula is C11H9I3N2O4, Recommanded Product: Diatrizoic Acid.
Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem